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group was 92% compared with 88% for the vancomycin group
(P < 0.0001). The lower costs for patients treated with linezolid
were attributable to the switch to oral therapy and earlier hos-
pital discharge. CONCLUSIONS: A higher cure rate in combi-
nation with lower overall treatment costs distinguishes linezolid
as a dominant therapy option compared with vancomycin in
patients with proven or suspected MRSA cSSTI.
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OBJECTIVES: To asses the cost-effectiveness of linezolid (600
mg IV, every 12h for 10 days), compared with vancomycin (1g
IV, every 12h for 10 days) for the treatment of ventilator-asso-
ciated pneumonia (VAP). METHODS: A decision model analy-
sis was performed from the National Health System perspective.
The primary outcome was the incremental cost-effectiveness of
linezolid in terms of cost per added QALY gained. The secondary
outcome was the marginal cost per year of life saved (YLS) gen-
erated by using linezolid. Clinical cure and survival rates 
estimates were derived from a retrospective analysis of two ran-
domized, double-blind trials comparing linezolid with van-
comycin. QALY were based on time-trade off study. Four subsets
of VAP patients were considered: all, with Gram-positive (GP),
with S. aureus (SA) and with methicillin-resistant SA (MRSA)
infection. Resources use and unit costs (2003€) were obtained
from Spanish VAP treatment guidelines and Spanish health costs
databases. Costs were evaluated for the acquisition of antibiotic
treatments, adverse reactions treatment, and antibiotic rescue,
extra diagnostic tests, the intensive care unit stay and medical
visits due to therapeutic failure. RESULTS: The additional QALY
and YLS per linezolid-treated patients were 0.392, 0.688, 0.606,
1.805 and 0.471, 0.829, 0.729, 2.175, respectively, compared
with that of vancomycin (all, GP, SA and MRSA VAP, respec-
tively). The additional cost per QALY gained obtained with 
linezolid was 1803.87€, 997.25€, 1149.00€ and 348.85€, respec-
tively. The additional cost per YLS obtained with linezolid was
1501.31€, 827.63€, 955.13€ and 289.51€, respectively. These
values are well below the acceptable threshold in Spain of
30,000€ per QALY/YLS gained. The sensitivity analyses con-
ﬁrmed the robustness of the base case analysis. CONCLU-
SIONS: According to this model, linezolid is a cost-effective
alternative to vancomycin for VAP patients in Spain, with an
additional cost per QALY/YLS gained below the acceptable
threshold for new therapies.
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OBJECTIVES: Hepatitis C (HCV) is a serious health problem
affecting around 170 million people worldwide. A considerable
health care burden is expected over the short to medium term,
because of earlier peaks in incidence rates and the presence of
undetected cases. The aim of the present study was to measure
resource use and direct costs associated with the management of
hepatitis C patients in a hospital-based Gastroenterology and
Hepatology Service (GAS). METHODS: A model of patient ﬂow
through the department was constructed, and expert opinion
was used to deﬁne relevant clinical sub-groups. Hospitalizations,
outpatient care and diagnostic tests for the group as a whole and
for each clinical sub-categoriy were calculated for the 4 month
study period using information from hospital records, depart-
ment protocols, and expert opinion. Unit costs were obtained
from the hospital administrative database. Antiviral treatments
were not included as they are not ﬁnanced from the GAS budget.
RESULTS: Data on use of resources and costs were obtained for
a total of 584 patients. The total cost of treating HCV patients
in the GAS for the study period was 600,343€ (1028€ per
patient). A total of 52% of these costs were attributable to diag-
nostic tests, 45% to hospitalization, and 3% to outpatient visits
two. The most costly clinical categories in overall terms were
post-transplant patients and chronic hepatitis patients, with total
costs for the 4-month study period of 136,185€ and 116,502€,
respectively. The two clinical categories with the highest per-
patient costs were pre-transplant decompensated cirrhosis and
hepatocarcinoma in decompensated cirrhosis, with per-patient
costs for the study period of 4731€ and 4498€, respectively. Hos-
pitalization was the principal cost driver in both instances. CON-
CLUSIONS: The study is useful in providing resource use and
cost information by clinical sub-categories which will help esti-
mate future resource use needs for these patients.
PIN6
CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF
ANTIVIRAL COMBINATION THERAPY WITH PEGINTERFERON
ALFA-2B AND RIBAVIRIN FOR CHRONIC HEPATITIS C
ADMINISTERED ACCORDING TO THE NEW GENOTYPE-
SPECIFIC GUIDELINES
Siebert U1, Sroczynski G1,Aidelsburger P2, Rossol S3,Wasem J2,
Manns MP4, McHutchison JG5,Wong JB6
1Harvard Medical School, Boston, MA, USA; 2University of Duisburg-
Essen, Duisburg-Essen, Germany; 3University of Mainz, Ruesselsheim,
Germany; 4Medical School of Hanover, Hanover, Germany; 5Scripps
Clinic, La Jolla, CA, USA; 6Tufts University School of Medicine, Boston,
MA, USA
OBJECTIVES: To evaluate lifetime clinical effectiveness and
cost-effectiveness of different antiviral treatment (AVT) strategies
in patients with chronic hepatitis C (CHC) using recent German
guidelines, that recommend basing drug dosage, intended treat-
ment duration and early stopping rules on the genotype of the
hepatitis C virus (HCV). METHODS: The German Hepatitis C
Model (GEHMO), a validated Markov model, was used to
project clinical events, life expectancy, QALYs, and lifetime costs
for the following AVT strategies: 1) no AVT (NoAVT); 2) Inter-
feron alfa-2b plus ribavirin for 48 weeks (IFN); 3) Peginterferon
alfa-2b plus ribavirin for 48 weeks (PEG); and 4) Peginterferon
alfa-2b plus ribavirin according to the German guidelines with
genotype-dependent AVT duration, dosing and early stoppage in
HCV-positive patients after 12 weeks (GUIDE). Incremental
cost-effectiveness ratios (ICER) were calculated from a societal
perspective. Clinical and drug utilization data were derived from
a clinical trial and from a survey of German hepatologists.
RESULTS: Combination therapy with peginterferon alfa-2b and
ribavirin (PEG or GUIDE) reduced the 20-year risk for decom-
pensated cirrhosis, hepatocellular carcinoma, liver transplanta-
tion, and liver-related death by more than 50%, compared to no
antiviral treatment. PEG increased life expectancy by 5.0 life
years and GUIDE increased life expectancy by 4.9 years com-
pared to NoAVT. GUIDE dominated IFN, so compared to
NoAVT, discounted ICERs were 1500€/QALY for GUIDE and
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3300€/QALY for PEG. GUIDE saved 3950€ per patient. Moving
from GUIDE to PEG was associated with an ICER >100,000
EUR/QALY. CONCLUSIONS: Administering combination
therapy with peginterferon alfa-2b and ribavirin in accordance
with the new German guidelines should allow tailoring treatment
efﬁciently to HCV genotype, body weight, and early viral
response in patients with minimal loss of effectiveness. Antiviral
treatment according to the new German guidelines and should
be cost-effective compared to other well-accepted medical 
interventions.
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OBJECTIVES: To assess the efﬁciency of long-term prophylaxis
with oral valganciclovir versus sequential intravenous/oral gan-
ciclovir in the prevention of cytomegalovirus (CMV) infection
and disease in solid organ transplant recipients. METHODS: A
cost minimization analysis was performed from the perspective
of the Spanish National Health System and differential direct
medical costs between both treatments were considered. The efﬁ-
cacy data of valganciclovir regime was obtained from Paya et
al.’s clinical trial (Am J Transplant 2004:611–20). It was con-
ducted a literature review of published clinical trials in order to
obtain the efﬁcacy data of high-risk transplant patients (D+R-)
treated with sequential intravenous/oral ganciclovir. Resource
use, including medication, in the prophylactic treatment with
intravenous/oral ganciclovir were retrieved from published liter-
ature and a retrospective review of 83 clinical charts of kidney,
liver and lung transplant patients in 9 Spanish hospitals. The
resources used with valganciclovir were retrieved from Paya et
al.’s clinical trial. The unit costs of resources were obtained from
national databases (2003€). The results of the study were
expressed in terms of average cost per patient treated with intra-
venous/oral ganciclovir and valganciclovir. RESULTS: At 12
months post-transplantation, the incidence rate of CMV infec-
tion and disease of high risk transplant patients of both long-
term prophylactic regimes were comparable (Kletzmayr J et al.
Transplantation 2000;70:1174–80; Paya et al. 2004). The
average cost of patient treated with valganciclovir and sequen-
tial intravenous/oral ganciclovir was 3295.9€ and 3715.51€,
respectively. The higher overall costs of intravenous/oral ganci-
clovir therapy, compared to oral valganciclovir are due to higher
drug administration costs. CONCLUSIONS: Long-term pro-
phylaxis with oral valganciclovir is a cost-saving option com-
pared to sequential intravenous/oral ganciclovir with similar
efﬁcacy rates, thus the oral therapy is a more efﬁcient strategy
in the prevention of CMV infection and disease in solid organ
transplantation.
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OBJECTIVES: To describe the changes in costs of care for HIV-
positive patients in Italy resulting from the diffusion of new anti-
retroviral combination therapies (HAART). METHODS: In all,
5422 patients from the I.CO.N.A. cohort (Italian Cohort Naive
Antiretrovirals) were followed between 1997 and 2002. This
multi-centric observational study includes adult HIV patients
naïve to antiretroviral therapies. Costs included antiretroviral
therapies (ART), hospital admissions, prophylaxis and treat-
ments for opportunistic infections, and main immuno-virologi-
cal exams. The perspective was that of the National Health
Service. Costs calculated retrospectively and expressed in con-
stant 1997 prices. RESULTS: In the 6-year period considered,
the number of AIDS Deﬁning Events per person-year decreased
from 106 to 26 per thousand, and the number of deaths per
person-year fell from 29 to 8 per thousand. Similarly, hospital-
izations decreased from an annual average of 9.6 days of admis-
sion per patient in 1997 to 0.9 days in 2002. Consequently,
admission costs per person-year decreased from 2.148 euro in
1997 to 256 in 2002, while the average annual costs of ART
increased from 2.145 to 3.149 euro. In only 2 years (from 1997
to 1999), ART costs increased from 42.3% to 85.9% of the total,
while admission costs decreased from 42.3% to 7% and pro-
phylactic treatments from 7.3% to 1.7%. The breakdown of
ART costs shows dual therapies (still widespread at the begin-
ning of the observation period) decreased over time in favor of
HAART, falling from 26.8% in 1997 to 5.9% in 2002. Patients
with fewer than 5 treatment switches had lowest costs distribu-
tions over the entire observation period. CONCLUSIONS: From
1997 to 2002 inpatient costs progressively decreased in favor of
antiretroviral therapy. Annual average costs per patient also
decreased, while total direct costs increased over time: health
resources, ﬁrst concentrated on hospitalized patients were then
distributed over a growing number of subjects.
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OBJECTIVES: When to initiate antiretroviral therapy for
asymptomatic patients remains uncertain. We assessed the costs-
effectiveness of starting highly active antiretroviral therapy
(HAART) at different CD4 cells counts (main predictors of prog-
nosis) as it emerged from Italian clinical practice in recent years.
METHODS: The study considered 3250 HAART-naïve patients
of the I.CO.N.A. cohort (Italian Cohort Naive Antiretrovirals),
enrolled and followed between 1997 and 2002. In correspon-
dence to >= 500, 350–499 and 200–349 CD4 cells/mm3, we
selected immediate and deferred groups accounting for lead time
bias. To assess the effects of early treatment on AIDS-free sur-
vival, we calculated propensity scores to represent the probabil-
ity of early HAART initiation and then estimated separate Cox
models stratiﬁed on propensity score blocks. The average effects
of early vs. deferred treatment on total health costs were
obtained similarly stratifying by propensity score blocks. The
incremental cost-effectiveness ratio (ICER) and the cost-
effectiveness acceptability curve were also derived. RESULTS:
Adjusted for propensity scores there was no difference in the rate
of AIDS/death in those patients who deferred HAART below 500
or 350 CD4 cells/mm3; we found instead a signiﬁcant difference
for immediate HAART at 200–349 CD4 cells/mm3, with a
hazard ratio of 0.32 (95% CI: 0.17–0.61). The average differ-
ence in total costs across propensity score strata was always
